MA5-12278

antibody from Invitrogen Antibodies

Targeting: PTEN BZS, MHAM, MMAC1, PTEN1, TEP1

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-12278

Provider

Invitrogen Antibodies

Product name

PTEN Monoclonal Antibody (17.A)

Antibody type

Monoclonal

Antigen

Recombinant full-length protein

Description

MA5-12278 targets PTEN in WB, IHC and ICC/IF applications and shows reactivity with Human and Mouse samples. The MA5-12278 immunogen is recombinant human PTEN protein.

Reactivity

Human, Mouse

Host

Mouse

Isotype

IgM

Antibody clone number

17.A

Vial size

500 µL

Concentration

Conc. Not Determined

Storage

4° C

References

Submitted references

WP1066 induces cell death in a schwannomatosis patient-derived schwannoma cell line.

Allaf A, Victoria B, Rosario R, Misztal C, Humayun Gultekin S, Dinh CT, Fernandez-Valle C
Cold Spring Harbor molecular case studies 2022 Jun;8(4)

---

Immunopathologic Assessment of PTEN Expression.

Castillo-Martin M, Thin TH, Collazo Lorduy A, Cordon-Cardo C
Methods in molecular biology (Clifton, N.J.) 2016;1388:23-37

---

A study on promoter methylation of PTEN in sporadic breast cancer patients from North India.

Siddiqui S, Akhter N, Deo SV, Shukla NK, Husain SA
Breast cancer (Tokyo, Japan) 2016 Nov;23(6):922-931

---

Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.

Lu B, Chen Q, Zhang X, Cheng L
Diagnostic pathology 2016 Jun 4;11(1):46

---

IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.

Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse JT, Sav MA, Flanagan A, Günel M, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K
Scientific reports 2016 Jun 10;6:27569

---

Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model.

Eritja N, Santacana M, Maiques O, Gonzalez-Tallada X, Dolcet X, Matias-Guiu X
Methods (San Diego, Calif.) 2015 May;77-78:31-40

---

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.

Cejas P, López-Gómez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Díaz E, Burgos E, Gonzalez-Barón M, Feliu J
Current cancer drug targets 2012 Feb;12(2):124-31

---

Identification of prognostic biomarkers for glioblastomas using protein expression profiling.

Jung Y, Joo KM, Seong DH, Choi YL, Kong DS, Kim Y, Kim MH, Jin J, Suh YL, Seol HJ, Shin CS, Lee JI, Kim JH, Song SY, Nam DH
International journal of oncology 2012 Apr;40(4):1122-32

---

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.

Teng HW, Wang HW, Chen WM, Chao TC, Hsieh YY, Hsih CH, Tzeng CH, Chen PC, Yen CC
Journal of surgical oncology 2011 Jun;103(8):773-81

---

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.

Skírnisdóttir I, Seidal T
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011 Aug;21(6):1024-31

---

Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer.

Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, Yatabe Y, Imai T, Ohashi Y
Breast (Edinburgh, Scotland) 2010 Oct;19(5):370-6

---

Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.

Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y
Proceedings of the National Academy of Sciences of the United States of America 2010 Jul 6;107(27):12210-5

---

PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.

Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H, Zhu H
Experimental and molecular pathology 2010 Feb;88(1):150-5

---

Deletion of Pten in pancreatic ß-cells protects against deficient ß-cell mass and function in mouse models of type 2 diabetes.

Wang L, Liu Y, Yan Lu S, Nguyen KT, Schroer SA, Suzuki A, Mak TW, Gaisano H, Woo M
Diabetes 2010 Dec;59(12):3117-26

---

Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified.

Gazzola A, Bertuzzi C, Agostinelli C, Righi S, Pileri SA, Piccaluga PP
Haematologica 2009 Jul;94(7):1036-7

---

Comparison of placental PTEN and beta1 integrin expression in early spontaneous abortion, early and late normal pregnancy.

Tokyol C, Aktepe F, Hüsniye Dilek F, Yilmazer M
Upsala journal of medical sciences 2008;113(2):235-42

---

Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.

Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciriş M
Pathology, research and practice 2007;203(3):153-62

---

Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.

Volante M, Saviozzi S, Rapa I, Ceppi P, Cappia S, Calogero R, Novello S, Borasio P, Papotti M, Scagliotti GV
Cancer 2007 Sep 15;110(6):1321-8

---

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.

Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jun 15;13(12):3577-84

---

PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.

Kolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM, Konopka B, Kupryjańczyk J
Gynecologic oncology 2006 Nov;103(2):692-7

---

Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer.

Deng H, Wu RL, Zhou HY, Huang X, Chen Y, Liu LJ
World journal of gastroenterology 2006 Feb 21;12(7):1013-7

---

Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.

Osman I, Dai J, Mikhail M, Navarro D, Taneja SS, Lee P, Christos P, Shen R, Nanus DM
Cancer 2006 Dec 1;107(11):2628-36

---

Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R
American journal of clinical pathology 2005 Sep;124(3):392-401

---

The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.

Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO
The Journal of pathology 2004 Sep;204(1):93-100

---

Proliferation kinetics in adenomyosis during the menstrual cycle and during oral contraceptive use.

Maia H Jr, Maltez A, Studart E, Athayde C, Coutinho EM
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2004 Feb;18(2):101-6

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of PTEN was performed by loading 25 µg of MCF-7 (lane 1), HepG2 (lane 2), Hela (lane 3) and NIH-3T3 (lane 4) cell lysates onto an SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked at 4ºC overnight. The membrane was probed with a PTEN monoclonal antibody (Product # MA5-12278) at a dilution of 1:50 overnight at 4°C, washed in TBST, and probed with an HRP-conjugated secondary antibody for 1 hr at room temperature in the dark. Chemiluminescent detection was performed using Pierce ECL Plus Western Blotting Substrate (Product # 32132). Results show a band at ~47 kDa.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of PTEN (green) showing staining in the cytoplasm of MCF-7 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a PTEN monoclonal antibody (Product # MA5-12278) in 3% BSA-PBS at a dilution of 1:10 and incubated overnight at 4 ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of PTEN (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a PTEN monoclonal antibody (Product # MA5-12278) in 3% BSA-PBS at a dilution of 1:10 and incubated overnight at 4 ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry analysis of PTEN showing positive staining in the cytoplasm and nucleus of paraffin-treated Human breast carcinoma (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN monoclonal antibody (Product # MA5-12278) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry analysis of PTEN showing positive staining in the cytoplasm and nucleus of paraffin-treated Human prostate tissue (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN monoclonal antibody (Product # MA5-12278) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.